Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
307 hedge funds and large institutions have $7.35B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2022 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 114 increasing their positions, 113 reducing their positions, and 30 closing their positions.
87% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 30
23% more call options, than puts
Call options by funds: $115M | Put options by funds: $93.6M
8% more funds holding
Funds holding: 284 → 307 (+23)
1% more repeat investments, than reductions
Existing positions increased: 114 | Existing positions reduced: 113
12% less capital invested
Capital invested by funds: $8.37B → $7.35B (-$1.03B)
17% less funds holding in top 10
Funds holding in top 10: 12 → 10 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$162M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$94.3M |
| 3 |
O
OrbiMed
New York
|
+$89.7M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$77M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$61.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$290M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$63.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$49.5M |
| 4 |
BAMCO Inc
New York
|
-$27.3M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$25.7M |
BHVN Hedge Fund Activity: Q1 2022 in Review
307 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2022, worth a combined $7.35B — down 12% from $8.37B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new BHVN positions and 30 closed out — a net gain of 26 holders — while 114 added to existing stakes and 113 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $162M. The largest seller was Capital International Investors, cutting an estimated $290M.
- 307 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2022, up from 284 in Q4 2021.
- Funds reported $7.35B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2022, down 12% quarter-over-quarter.
- 56 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2022 and 30 closed out, a net change of +26 holders.
- The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q1 2022 was Janus Henderson Group, an estimated $162M added.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2022 was Capital International Investors, an estimated $290M sold.
Based on aggregated 13F filings for Q1 2022.